What change did Evercore ISI make on Feb 25, 2026 for MDLN?

Evercore ISI maintained an Outperform rating on MDLN and raised the price target to $55 from $50 on Feb 25, 2026. The move reflects strong momentum, including $2.4 billion of new customer signings and fiscal 2026 organic growth guidance.

Does a maintained Outperform count as a MDLN upgrade or downgrade?

A maintained Outperform is neither an upgrade nor a downgrade; it signals continued positive conviction. The firm increased the MDLN price target, which raises upside expectations without changing the qualitative stance.

How should investors use the MDLN analyst rating and price target?

Investors should view the MDLN analyst rating and $55 price target as one input. Combine it with Medline’s guidance, earnings, market cap, and Meyka AI signals before adjusting positions or sizing exposure.

Will the Evercore note likely move MDLN stock near term?

Analyst notes can move sentiment. The Feb 25, 2026 Evercore action coincided with a reported **-2.07% ($-1.02)** price move in the entry data, showing short-term volatility can occur even with positive analyst updates.

Analyst Ratings

Evercore ISI Maintains Outperform on Medline Inc (MDLN) Feb 25 2026

ByHuzaifa Zahoor February 26, 2026

The MDLN analyst rating update from Evercore ISI on February 25, 2026 kept an Outperform call and raised the price target to $55 from $50. This maintained rating and target increase signal continued confidence after strong fourth quarter results and new customer signings. Investors should note Evercore ISI’s view ties directly to management’s fiscal 2026 guidance of 8% to 9% organic sales growth. Evercore ISI’s action is the only public rating change reported on this date for Medline Inc.